Rimegepant for Acute Migraine: Pooled Efficacy and Tolerability

Key Takeaways

• Two-hour pain freedom was higher with single-dose oral rimegepant 75 mg than with placebo in pooled placebo-controlled trials.
• Sustained pain freedom from 2 to 24 hours also favored rimegepant across the randomized evidence base.
• Overall adverse-event rates were similar, risk of bias was low, and the authors described modest but clinically meaningful efficacy with favorable short-term tolerability.

In a systematic review and meta-analysis of randomized trials, single-dose oral rimegepant 75 mg was linked with higher 2-hour pain freedom than placebo in adults with acute migraine, 19.8% versus 10.7%.

The review pooled seven double-blind randomized controlled trials involving 6,734 participants. Eligible studies enrolled adults aged 18 years or older with migraine, with or without aura, who received a single 75 mg oral dose or placebo for acute attacks. The trial set included one phase II study, five phase III studies, and one phase IV study. Methods included PRISMA-concordant study selection, Cochrane RoB 2 risk-of-bias assessment, GRADE certainty assessment, and searches through December 2025.The analysis addressed treatment of acute migraine attacks rather than prevention, with the co-primary outcomes being pain freedom at 2 hours and sustained pain freedom from 2 to 24 hours.

For 2-hour pain freedom, the pooled relative effect favored rimegepant, with a risk ratio of 1.93, a 95% confidence interval of 1.51 to 2.47, and P<0.001. Sustained pain freedom from 2 to 24 hours occurred in 14.2% of rimegepant recipients and 6.3% of placebo recipients, with a risk ratio of 2.39, a 95% confidence interval of 1.75 to 3.27, and P<0.001. The corresponding numbers needed to treat were 10 and 11, respectively.

Short-term tolerability was assessed through overall adverse events after dosing. Adverse events were reported in 14.3% of participants receiving rimegepant and 12.7% receiving placebo. The pooled estimate was a risk ratio of 1.14 with a 95% confidence interval of 1.00 to 1.30, with P=0.056 and a number needed to harm of 55. No statistically significant between-group difference was identified.

Risk of bias was judged low across the included trials. The authors characterized rimegepant 75 mg as showing modest yet clinically meaningful efficacy with favorable short-term tolerability for acute migraine attacks. They also stated that the findings support use in adults with inadequate response, contraindications, or intolerance to first- or second-line therapies. The review framed rimegepant as a supported acute-treatment option within the limits of this evidence base.